Form D Explorer
Grace Therapeutics, Inc. · CIK 1444192

Report a data issueCitable research briefCompare issuerPrivate research collection

Grace Therapeutics, Inc.

CIK 1444192 · Corporation · Inc. DELAWARE · PRINCETON, New Jersey · Pharmaceuticals

These Form D notices describe private placements reported to the SEC. Read Form D/A amendments alongside the original disclosures.

Filings
2
Original notices
2
Amendments
0
Activity
Feb 25, 2025
through Aug 11, 2026

Figures are issuer-reported and describe stored filings. Data coverage and methodology.

Differences between reported disclosures

Same issuer CIK; offering identity has not been established. Differences are arithmetic comparisons between disclosures, not additional capital raised, new investors or confirmed amendments to the same offering.

Unavailable values are shown as a dash; reported zero remains zero.
FieldFeb 25, 2025 · DAug 11, 2026 · DLater minus earlier
Reported offering amount$30,000,203$9,999,998$-20,000,205
Reported amount sold$14,999,985$9,999,998$-4,999,987
Reported investor count—9—
Reported minimum investment$1$1$0

Earlier SEC source: 0001140361-25-005827 · Later SEC source: 0001123292-26-001084

Choose filings to compare · Research this issuer step by step

Latest available filing snapshot: how to read these fields

Form D · Aug 11, 2026

Reported offering amount
$9,999,998
Reported exemptions
Rule 506(b)
Reported amount sold
$9,999,998

This is one filing's disclosure, not the issuer's lifetime fundraising or current offering status.

Filings by year

Submission counts, including amendments; not dollars raised or distinct funding rounds.

Same reported sales compensation recipient

Matches in stored disclosures are research leads. They do not establish common ownership or confirm identity.

Form D filings (2)